Home > News > Small: a simple synthesis of organic gadolinium nanoparticles for tumor magnetic resonance imaging

Small: a simple synthesis of organic gadolinium nanoparticles for tumor magnetic resonance imaging

wallpapers News 2020-07-11

gadolinium based contrast agents have occupied most of the global market share of clinical magnetic resonance imaging (MRI) contrast agents for many years including 40% of the whole body parts 60% of the nerve parts. However in 2006 studies have shown that this kind of contrast agent will produce nephrotoxicity in vivo due to the leakage of gadolinium ions then lead to renal fibrosis. Based on this the U.S. Food Drug Administration (FDA) issued a safety warning for the use of such drugs. In addition the FDA confirmed the brain deposition of gadolinium based contrast agents in May 2017 said that it would continue to evaluate the safety of gadolinium based contrast agents. Some linear GD based contrast agents in EU countries have been removed. In order to reduce the toxicity it has become an increasing goal for researchers to develop gadolinium based contrast agents with better MRI relaxation effect to reduce the clinical dose.

for this reason researcher Wu Aiguo of Ningbo Institute of materials technology engineering Chinese Academy of Sciences cooperated with Professor Shen Zheyu Qiu Xiaozhong of School of Biomedical Engineering Southern Medical University to develop a simple synthesis method of gadolinium based contrast agent. This method can easily synthesize 10 gram organic Gadolinium Complex Nanoparticles (gdsalnps RBSA) in the laboratory The nanoparticles have high R1 value (19.51 mm-1 s-1) very low R2 / R1 ratio (1.21). The experimental results in tumor bearing mice show that the organic gadolinium composite nanoparticles can be used as a potential new gadolinium based MRI contrast agent for high contrast T1 weighted MRI of tumors which has a great industrial prospect. The study was recently published in small (small 2020 1906870 DOI: 10.1002/small. 201906870). In this method gadolinium salicylate nanoparticles (gdsalnps) were formed by the coordination bond intermolecular force between gadolinium ion (Gd3 ) salicylate ion (SAL ^) under mild aqueous conditions by precisely adjusting the reaction parameters further loaded with reduced bovine serum albumin (RBSA). After tail vein injection gdsalnps RBSA was transported to tumor tissue through passive targeting enriched in tumor tissue through high permeability long retention effect (EPR) of solid tumor. Because RBSA is rich in functional groups such as amino carboxyl groups Gd ions in gdsalnps RBSA are firmly locked which is not easy to release in the body circulation thus avoiding the toxicity. The gadolinium based composite nanoparticles based on reduced bovine serum albumin have good biological safety its excellent MRI performance has been successfully applied to the diagnosis of breast cancer in vivo showing good clinical potential. More importantly ten gram gdsalnps RBSA nanoparticles can be easily synthesized in the laboratory. As a high-performance MRI contrast agent gdsalnps RBSA nanoparticles have great clinical application prospects.

TRUNNANO (aka. Luoyang Tongrun Nano Technology Co. Ltd.) is a trusted global chemical material supplier & manufacturer with over 12 years' experience in providing super high-quality chemicals and Nanomaterials. Our company has successfully developed a series of powder materials (including oxides, carbides, nitrides, single metal, etc.), high-purity targets, functional ceramics, and structural devices. OEM service is available. Please contact us if necessary.
Say something
  • All comments(0)
    No comment yet. Please say something!